#SLNO

Thiard News@F4F

@newsen.bsky.social

8 hours ago

Soleno Therapeutics Faces Class Action Lawsuit for Alleged Securities Fraud Impacting Investors Soleno Therapeutics, Inc. faces a securities fraud class-action lawsuit regarding misrepresentations related to its clinical trials. Investors affected have until May 2026 to act.

Soleno Therapeutics Faces Class Action Lawsuit for Alleged Securities Fraud Impacting Investors #USA #California #Securities_Fraud #Soleno_Therapeutics #SLNO

StockTitan

@stocktitan.net

2 days ago

SLNO Lawsuit Alleges Allegedly Conducting Sham Clinical Trials - Soleno Therapeutics, Inc. Investors Face Losses Following Allegedly Conducting Sham Clinical Trials: SueWallSt {"summary":"","positive":[],"negative":[],"faq":[]}

#SLNO SLNO Lawsuit Alleges Allegedly Conducting Sham Clinical Trials - Soleno Therapeutics, Inc. Investors Face Losses Following Allegedly Conducting Sham Clinical Trials: SueWallSt

www.stocktitan.net/news/SLNO/slno-lawsuit-a...

StockTitan

@stocktitan.net

2 months ago

Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism Soleno Therapeutics (NASDAQ: SLNO) announced publication in the Journal of Clinical Endocrinology and Metabolism of results from a 16-week randomized withdrawal study (C602-RWP) of VYKAT XR (diazoxide choline extended-release) in people ≥4 years with hyperphagia in Prader-Willi syndrome (PWS).The study randomized 77 participants (VYKAT XR n=38; placebo n=39). Withdrawal to placebo produced statistically significant worsening in hyperphagia (HQ-CT, P=0.0022). Placebo participants gained more weight (LS mean difference -1.6 kg; 95% CI -3.1, -0.1) and had larger BMI z-score increases (LS mean difference -0.09; 95% CI -0.17, -0.01). No serious adverse events occurred in the VYKAT XR arm.

#SLNO Soleno Therapeutics Announces Publication of Results from Pivotal Study of VYKAT™ XR in the Journal of Clinical Endocrinology and Metabolism

www.stocktitan.net/news/SLNO/soleno-therape...

InsiderFinance

@insiderfinance.com

2 months ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#PZZA, #SLNO, #PBR, #CPRT, #XEL

#OptionFlow #OptionsTrading #Trading

Thiard News@F4F

@newsen.bsky.social

2 months ago

Johnson Fistel Investigates Soleno Therapeutics Shareholder Losses Due to Alleged Securities Violations Johnson Fistel launches an investigation into Soleno Therapeutics on behalf of shareholders facing losses from alleged securities law violations. The inquiry focuses on misleading statements regarding the drug VYKAT™ XR.

Johnson Fistel Investigates Soleno Therapeutics Shareholder Losses Due to Alleged Securities Violations #United_States #San_Diego #Johnson_Fistel #Soleno_Therapeutics #SLNO

InsiderFinance

@insiderfinance.com

2 months ago

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #PZZA 6.1x
2. #SLNO 3.2x
3. #PBR 3.0x
4. #CPRT 2.9x
5. #XEL 2.5x

#OptionFlow #OptionsTrading #Trading

StockTitan

@stocktitan.net

4 months ago

Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement Soleno Therapeutics (NASDAQ: SLNO) entered an $100 million Accelerated Share Repurchase (ASR) with Jefferies on Nov 11, 2025, with an initial payment of $100 million and an initial delivery of ~1,511,553 shares based on the Nov 10, 2025 close. The final repurchased share count will be adjusted by the volume-weighted average price during the ASR term. The company said the ASR supports confidence after achieving profitability in Q3 2025. The ASR is expected to complete in Q1 2026.

#SLNO Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement

www.stocktitan.net/news/SLNO/soleno-therape...

Thiard News@F4F

@newsen.bsky.social

4 months ago

Edelson Lechtzin LLP Highlights Investigation of Soleno Therapeutics for Potential Securities Violations Edelson Lechtzin LLP is probing Soleno Therapeutics for potential federal securities law violations and is urging impacted investors to reach out.

Edelson Lechtzin LLP Highlights Investigation of Soleno Therapeutics for Potential Securities Violations #United_States #Newtown #Edelson_Lechtzin_LLP #Soleno_Therapeutics #SLNO

StockTitan

@stocktitan.net

4 months ago

Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the third quarter ended September 30, 2025 and provided an

#SLNO Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR

www.stocktitan.net/news/SLNO/soleno-therape...

Thiard News@F4F

@newsen.bsky.social

5 months ago

Rosen Law Firm Investigates Potential Class Action for Soleno Therapeutics Investors Amid Misleading Claims Rosen Law Firm is investigating potential securities claims for investors of Soleno Therapeutics, Inc. after allegations of misleading information. Join the class action for recovery.

Rosen Law Firm Investigates Potential Class Action for Soleno Therapeutics Investors Amid Misleading Claims #USA #New_York #Rosen_Law_Firm #Soleno_Therapeutics #SLNO

Thiard News@F4F

@newsen.bsky.social

5 months ago

Pomerantz Law Firm Investigates Soleno Therapeutics Investors' Claims for Possible Securities Fraud Pomerantz LLP is currently exploring potential securities fraud allegations concerning Soleno Therapeutics, Inc. as a response to a negative report impacting stock prices.

Pomerantz Law Firm Investigates Soleno Therapeutics Investors' Claims for Possible Securities Fraud #USA #New_York #Pomerantz_LLP #SLNO #Solen_Therapeutics

Thiard News@F4F

@newsen.bsky.social

5 months ago

Pomerantz Law Firm Investigates Soleno Therapeutics, Inc. For Investor Claims Pomerantz LLP is probing potential securities fraud claims against Soleno Therapeutics, Inc. following a critical report on its product.

Pomerantz Law Firm Investigates Soleno Therapeutics, Inc. For Investor Claims #United_States #New_York #Pomerantz_LLP #Soleno_Therapeutics #SLNO

Thiard News@F4F

@newsen.bsky.social

5 months ago

Rosen Law Firm Seeks to Protect Soleno Therapeutics Investors Amid Class Action Investigation Rosen Law Firm is investigating Soleno Therapeutics, Inc. for potential securities claims after concerns were raised about misleading business information. Join now.

Rosen Law Firm Seeks to Protect Soleno Therapeutics Investors Amid Class Action Investigation #USA #New_York #Rosen_Law_Firm #Soleno_Therapeutics #SLNO

Thiard News@F4F

@newsen.bsky.social

5 months ago

Rosen Law Firm Investigates Class Action for Soleno Therapeutics Investors Amid Stock Decline Rosen Law Firm is actively investigating potential securities class action claims for investors of Soleno Therapeutics, following allegations of misleading information.

Rosen Law Firm Investigates Class Action for Soleno Therapeutics Investors Amid Stock Decline #USA #New_York #Rosen_Law_Firm #Soleno_Therapeutics #SLNO

Thiard News@F4F

@newsen.bsky.social

5 months ago

Rosen Law Firm Investigates Potential Class Action for Soleno Therapeutics Investors Amid Serious Allegations Rosen Law Firm is investigating potential securities claims for Soleno Therapeutics shareholders due to serious allegations. Discover your rights.

Rosen Law Firm Investigates Potential Class Action for Soleno Therapeutics Investors Amid Serious Allegations #United_States #New_York #Rosen_Law_Firm #Soleno_Therapeutics #SLNO

Thiard News@F4F

@newsen.bsky.social

5 months ago

Pomerantz Law Firm Investigates Securities Fraud Claims Against Soleno Therapeutics, Inc. Pomerantz LLP has launched an investigation into potential securities fraud regarding Soleno Therapeutics. Investors are encouraged to get in touch.

Pomerantz Law Firm Investigates Securities Fraud Claims Against Soleno Therapeutics, Inc. #United_States #New_York #Pomerantz_LLP #Soleno_Therapeutics #SLNO

Thiard News@F4F

@newsen.bsky.social

6 months ago

Pomerantz Law Firm Probes Investor Claims Against Soleno Therapeutics, Inc. Following Price Drop Pomerantz LLP is investigating potential securities fraud by Soleno Therapeutics, Inc. after a recent stock price plunge. Investors may be affected.

Pomerantz Law Firm Probes Investor Claims Against Soleno Therapeutics, Inc. Following Price Drop #United_States #New_York #Pomerantz_LLP #Soleno_Therapeutics #SLNO

Thiard News@F4F

@newsen.bsky.social

6 months ago

Rosen Law Firm Probes Securities Claims for Soleno Therapeutics Investors Amid Misleading Information Allegations Rosen Law Firm continues its investigation into potential securities claims for Soleno Therapeutics investors due to allegations of misleading information. A class action may be pursued.

Rosen Law Firm Probes Securities Claims for Soleno Therapeutics Investors Amid Misleading Information Allegations #USA #New_York #Rosen_Law_Firm #Soleno_Therapeutics #SLNO

Thiard News@F4F

@newsen.bsky.social

6 months ago

Pomerantz Law Firm Launches Investigation into Soleno Therapeutics Following Price Drop Pomerantz LLP is probing claims for Soleno Therapeutics investors after a sharp drop in stock prices following allegations brought forth by Scorpion Capital.

Pomerantz Law Firm Launches Investigation into Soleno Therapeutics Following Price Drop #United_States #New_York #Pomerantz_LLP #Soleno_Therapeutics #SLNO

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

7 months ago

Soleno (SLNO) Q2 Revenue Jumps 30% | The Motley Fool

#SLNO #ee3b7a39-17f6-4e4c-b273-92987dd3219a #data-news

Origin | Interest | Match

StockTitan

@stocktitan.net

7 months ago

Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results Soleno Therapeutics (NASDAQ:SLNO) reported significant progress in Q2 2025, highlighted by the successful launch of VYKAT XR, the first FDA-approved therapy for Prader-Willi Syndrome (PWS). Since its April 14 launch, the company has received 646 patient start forms from 295 unique prescribers, with coverage extending to over 100 million lives.The company reported Q2 2025 product revenue of $32.7 million and ended the quarter with $293.8 million in cash and equivalents. Additionally, Soleno raised $230 million through a stock offering in July. The company's Marketing Authorization Application (MAA) for VYKAT XR has been submitted to the European Medicines Agency (EMA) for PWS treatment approval in the EU.

#SLNO Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/SLNO/soleno-therape...

StockTitan

@stocktitan.net

8 months ago

Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock Soleno Therapeutics (NASDAQ: SLNO) has announced the pricing of its public offering of 2,352,941 shares of common stock at $85.00 per share, aiming to raise approximately $200 million in gross proceeds. The company has also granted underwriters a 30-day option to purchase up to 352,941 additional shares.The proceeds will primarily fund the commercialization of VYKATT™ XR, their recently FDA-approved therapy for hyperphagia in Prader-Willi syndrome patients. Additional funds will support EU regulatory activities, research and development, and general corporate purposes. The offering, managed by Goldman Sachs, Guggenheim Securities, TD Cowen, Cantor, and Oppenheimer, is expected to close around July 11, 2025.

#SLNO Soleno Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

www.stocktitan.net/news/SLNO/soleno-therape...

StockTitan

@stocktitan.net

8 months ago

Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock Soleno Therapeutics (NASDAQ:SLNO) has announced plans for a $200 million public offering of common stock, with an additional 30-day option for underwriters to purchase up to $30 million of shares. The offering will be managed jointly by Goldman Sachs and Guggenheim Securities.The proceeds will primarily fund the commercialization of VYKAT™ XR, their recently FDA-approved therapy for hyperphagia in Prader-Willi syndrome. Additional funds will support EU regulatory activities, research and development, and general corporate purposes. The offering will be made through a previously filed Form S-3ASR registration statement.

#SLNO Soleno Therapeutics Announces Proposed $200 Million Public Offering of Common Stock

www.stocktitan.net/news/SLNO/soleno-therape...

StockTitan

@stocktitan.net

8 months ago

Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025 Soleno Therapeutics (Nasdaq: SLNO) released preliminary Q2 2025 financial results, highlighting strong performance of its recently approved drug VYKAT™ XR. The company projects Q2 net revenue between $31.0-$33.0 million from VYKAT™ XR sales.Key metrics include $293.8 million in cash and equivalents, 646 patient start forms from 295 unique prescribers since VYKAT™ XR's March 26 approval, and $50.0 million in outstanding debt. The company notes these results are preliminary and subject to final review.

#SLNO Soleno Therapeutics Announces Preliminary Financial and Operational Results for the Second Quarter Ended June 30, 2025

www.stocktitan.net/news/SLNO/soleno-therape...

StockTitan

@stocktitan.net

8 months ago

New 4-Year Clinical Data Reveals VYKAT XR Outcomes in Prader-Willi Syndrome Treatment at ENDO 2025 Latest long-term efficacy data for VYKAT XR in treating Prader-Willi Syndrome spans 4+ years of treatment. Key glycemic and safety outcomes to be revealed. Get insights.

#SLNO Soleno Therapeutics Announces Two Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ENDO 2025

www.stocktitan.net/news/SLNO/soleno-therape...

StockTitan

@stocktitan.net

8 months ago

Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference Soleno Therapeutics (NASDAQ: SLNO) presented new data on VYKAT XR (diazoxide choline) for Prader-Willi Syndrome (PWS) treatment at the 2025 United in Hope conference. Two key findings were highlighted: First, VYKAT XR showed significant reduction in hyperphagia symptoms (p ≤ 0.0001) in patients under strict food control through Year 3. Second, the drug demonstrated similar efficacy in both pre-diabetic/diabetic and normoglycemic patients at Week 156 (p<0.0001).The study revealed that 60% of participants had pre-diabetes or diabetes at baseline. While hyperglycemia-related adverse events were higher in the pre-diabetic/diabetic group (42.7% vs 24.0%), they were generally manageable with low discontinuation rates (4.0% vs 6.0%).

#SLNO Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference

www.stocktitan.net/news/SLNO/soleno-therape...

StockTitan

@stocktitan.net

8 months ago

Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference Soleno Therapeutics (NASDAQ: SLNO) announced its participation in the 2025 United in Hope: International Prader-Willi Syndrome Conference with one oral and six poster presentations. The conference, scheduled for June 24-28, 2025, in Phoenix, AZ, is a historic collaboration between major PWS organizations and is expected to be the largest PWS-focused conference ever. The presentations focus on the company's DCCR tablets, covering topics including long-term efficacy results, swallowability, hyperphagia reduction, emotional impact, safety in pre-diabetic patients, fat mass changes, and food control parameters. Dr. Anish Bhatnagar, CEO, emphasized the importance of data, science, and advocacy in advancing rare disease treatments, particularly during the 50th anniversary of PWSA | USA.

#SLNO Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference

www.stocktitan.net/news/SLNO/soleno-therape...

StockTitan

@stocktitan.net

9 months ago

New Clinical Data Shows VYKAT XR Improves Body Mass and Behavior in Prader-Willi Syndrome Patients Latest VYKAT XR trial results reveal significant improvements in PWS patients. Two key presentations showcase long-term efficacy data at major endocrine conference. Learn more.

#SLNO Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at PES 2025

www.stocktitan.net/news/SLNO/soleno-therape...

StockTitan

@stocktitan.net

10 months ago

Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025 Soleno Therapeutics (NASDAQ: SLNO) announced two upcoming presentations at the ISPOR 2025 conference in Montreal, focusing on their drug VYKAT™ XR (diazoxide choline) for treating hyperphagia in Prader-Willi syndrome (PWS). The first presentation will discuss mortality rates and treatment outcomes from a Phase 3 clinical trial of VYKAT™ XR. The second presentation will examine the healthcare burden of PWS through analysis of emergency department visits and inpatient stays in US claims data. Both presentations will be delivered by Raj Gandhi, PharmD MBA on May 14 and 15, 2025.

#SLNO Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025

www.stocktitan.net/news/SLNO/soleno-therape...

StockTitan

@stocktitan.net

10 months ago

Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025 Soleno Therapeutics (NASDAQ: SLNO) announced upcoming presentations of data for VYKAT™ XR (diazoxide choline) at the Joint Congress of ESPE and ESE Meeting 2025 in Copenhagen. VYKAT XR, recently FDA-approved on March 26, 2025, is now available in the US for treating hyperphagia in Prader-Willi syndrome (PWS) patients aged 4 and older. Two presentations are scheduled: a poster on PWS's impact on caregivers and healthcare systems, and an oral presentation on long-term results of the drug's effects on behavior and hyperphagia reduction. PWS affects approximately 1 in 15,000 live births, characterized by hyperphagia - an intense, persistent hunger that can lead to severe health complications. Important safety information includes contraindications for patients with hypersensitivity to diazoxide or thiazides, warnings about hyperglycemia risks, and common side effects including hypertrichosis, edema, hyperglycemia, and rash.

#SLNO Soleno Therapeutics Announces Oral Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ESPE and ESE 2025

www.stocktitan.net/news/SLNO/soleno-therape...